Tiziana life sciences initiates multi-center phase 2a clinical trial of intranasal foralumab for non-active secondary progressive multiple sclerosis

New york, sept. 26, 2023 (globe newswire) -- tiziana life sciences ltd. (nasdaq: tlsa) (“tiziana” or the “company”), a biotechnology company developing breakthrough immunomodulation therapies via novel routes of delivery, today announced that it held an investigator's meeting with principal investigators at brigham and women's hospital, a founding member of mass general brigham healthcare system, to begin site initiation for its lead intranasal foralumab program entering phase 2a clinical testing in non-active secondary progressive multiple sclerosis (na-spms) patients. in total, six to ten new clinical trial sites will be recruited.
TLSA Ratings Summary
TLSA Quant Ranking